(Q64100193)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30704789%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

title

Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30704789%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30704789%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

Mark Thursz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30704789%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

Timothy B Hallett

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30704789%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

author name string

Alastair Heffernan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30704789%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

Graham S Cooke

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30704789%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

language of work or name

English

0 references

publication date

29 January 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30704789%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30704789%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

volume

393

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30704789%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

issue

10178

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30704789%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

page(s)

1319-1329

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30704789%20AND%20SRC:MED&resulttype=core&format=json

Natural history of hepatitis C

21 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Epidemiology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Evolution of the global burden of viral infections from unsafe medical injections, 2000-2010.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Global epidemiology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Epidemiology of hepatitis C: geographic differences and temporal trends

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Treating viral hepatitis C: efficacy, side effects, and complications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Sofosbuvir for previously untreated chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Mortality among people who inject drugs: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Extrahepatic manifestations of hepatitis C infection: navigating CHASM.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

The natural history of hepatitis C virus (HCV) infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Estimating and Projecting Trends in HIV/AIDS Generalized Epidemics Using Incremental Mixture Importance Sampling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Needle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

HIV and risk environment for injecting drug users: the past, present, and future.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Unnecessary injecting of medicines is still a major public health challenge globally

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe".

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Epidemiology of Injection Drug Use: New Trends and Prominent Issues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

What Can We Learn From The Portuguese Decriminalization of Illicit Drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

The successful implementation of Scotland's Hepatitis C Action Plan: what can other European stakeholders learn from the experience? A Scottish voluntary sector perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2932277-3

7 January 2021

Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group

1 reference

12 December 2020

Anthropological perspectives on injections: a review.

1 reference

12 December 2020

Natural history of chronic hepatitis C

1 reference

12 December 2020

Best infection control practices for intradermal, subcutaneous, and intramuscular needle injections.

1 reference

12 December 2020

Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures

1 reference

12 December 2020

Extrahepatic manifestations of chronic hepatitis C virus infection

1 reference

12 December 2020

10.1016/S0140-6736(18)32277-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30704789%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30704789%20AND%20SRC:MED&resulttype=core&format=json

21 April 2020

PubMed publication ID

30704789

1 reference